Valeant (VRX) Wellbutrin XL Pricing Strategy is Unsustainable - Wells Fargo's Maris

October 17, 2016 1:48 PM EDT Send to a Friend
Wells Fargo analyst David Maris said Valeant Pharmaceuticals (NYSE: VRX) Wellbutrin XL distribution is unclear and more importantly, its pricing ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login